Introduction
The European Organization for Research and Treatment of Cancer Quality of Life Core Function Questionnaire (EORTC QLQ-F17) is positioned at the forefront of patient-reported outcome measures in the evolving landscape of oncology, where capturing the patient’s voice through reliable metrics is essential for optimizing care. It serves as a shortened, focused patient-reported outcome measure. Specifically, this 17-item tool originates from the widely recognized EORTC QLQ-C30 to assess core functional domains more efficiently. Published in 2025 by a distinguished team of experts including Florian Zeman and Johannes M. Giesinger, the EORTC QLQ-F17 has already begun to gain traction in scientific literature (Zeman et al., 2025). Reflecting its immediate impact, the foundational study has already garnered one citation within its first year of publication.
This article explores the core features, psychometric properties, and clinical applications of the EORTC QLQ-F17. Furthermore, we aim to provide clinicians and researchers with actionable insights into how this instrument can be integrated into oncology workflows to enhance patient monitoring.
Key features of the European organization for research and treatment of cancer quality of life core function questionnaire (EORTC QLQ-F17)
Purpose and Use
The primary objectives of the European Organization for Research and Treatment of Cancer Quality of Life Core Function Questionnaire (EORTC QLQ-F17) include:
- Focused Patient-Reported Outcome: It serves as a streamlined instrument to capture the patient’s perspective on their health status efficiently.
- Core Functional Assessment: The primary goal is to assess the four essential functional domains in oncology:
- Physical Functioning: Monitoring the patient’s ability to perform daily physical tasks.
- Role Functioning: Evaluating how health affects work and routine activities.
- Emotional Functioning: Measuring the impact on mental and emotional well-being.
- Social Functioning: Assessing the effects of the disease on family and social interactions.
Target Population
The EORTC QLQ-F17 is validated for use with adults aged 18 and older, spanning various life stages:
- Young Adults (18–24 years)
- Middle-Aged Adults (25–44 years)
- Older Adults (45–64 years)
- Seniors (65+ years)
It is specific to oncology populations, making it suitable for patients at any stage of cancer diagnosis or treatment.
Structure
The questionnaire consists of 17 items, which categorize functioning into four multi-item functional scales and individual global health items. Each section captures a specific dimension of the patient’s experience:
- Physical Functioning (5 items): Assesses the ability to perform daily physical activities (Questions 1–5).
- Role Functioning (2 items): Evaluates how health affects work and daily activities (Questions 6–7).
- Emotional Functioning (4 items): Measures feelings and emotional well-being (Questions 8–11).
- Social Functioning (2 items): Examines the impact of health on family and social life (Questions 12–13).
In addition to these scales, the final four questions independently address financial difficulties, overall physical condition, overall quality of life, and overall health. This comprehensive structure ensures that no critical aspect of functional health is overlooked.
Scoring Method
The scoring system for the European Organization for Research and Treatment of Cancer Quality of Life Core Function Questionnaire (EORTC QLQ-F17) follows a meticulous structure to ensure both precision and comparability across clinical studies.
Scale Types and Measurement Formats: The instrument utilizes two distinct measurement formats to capture patient data effectively:
- Items 1 to 15: These questions focus on core functioning and symptoms, using a 4-point Likert scale (ranging from 1 = “Not at all” to 4 = “Very much”).
- Items 16 and 17: These questions assess Global Health and Quality of Life (QoL) using a 7-point scale (ranging from 1 = “Very poor” to 7 = “Excellent”).
Linear Score Transformation: To ensure comparability, all raw scores are converted into a standardized scale ranging from 0 to 100. A linear transformation formula achieves this:
Transformed Score = [1 – ((Raw Score – 1) / Range)] \times 100
Note: For items 1–15, the Range is 3, whereas for items 16 and 17, the Range is 6.
Interpretation of Results: For all functional scales within the EORTC QLQ-F17, a higher transformed score (closer to 100) represents a higher or better level of functioning, whereas a lower score indicates functional impairment.
Clinical Utility: The strategic use of the 4-point Likert scale ensures that the data remains consistent with the original EORTC QLQ-C30 framework, allowing for seamless integration into existing clinical databases and facilitating clear interpretation across different patient cohorts.
Administration Format
Because the EORTC QLQ-F17 offers high efficiency, it typically takes only 5 to 10 minutes to complete. It is primarily a self-administered questionnaire, meaning it requires no special training for the patient to complete it. The tool is highly versatile and supports several formats:
- Paper-based
- Digital (Online)
- In-person Interview
This versatility makes it a practical choice for modern healthcare environments, including telehealth and mobile health monitoring.
Application of the European organization for research and treatment of cancer quality of life core function questionnaire (EORTC QLQ-F17)
The clinical utility of this tool is extensive. Since it focuses on functional status, it is highly applicable in:
- Screening: Identifying patients who are experiencing significant functional decline.
- Monitoring: Tracking the impact of chemotherapy or radiation on a patient’s daily life over time.
- Treatment Planning: Providing data that can help clinicians tailor supportive care interventions.
- Research: Serving as a primary or secondary endpoint in clinical trials to measure the efficacy of new oncological treatments.
Languages and availability
To support international research, the EORTC QLQ-F17 is available in several key languages, including:
- English
- Spanish
- French
- German
Regarding access and cost, the questionnaire is a Paid instrument that requires official licensing. It operates under a Restricted Access model; while it features no financial charges for academic use, users must obtain formal and binding permission by signing an academic user agreement for each specific study.
Reliability and Validity
The EORTC QLQ-F17 is scientifically classified as a Highly Reliable and Valid instrument for oncology populations. A Cronbach’s alpha ranging from 0.73 to 0.89 highlights its robust psychometric profile, ensuring strong internal consistency across all functional scales.
- The original validation study: Study Link
Limitations and Considerations
Despite its strengths, the EORTC QLQ-F17 has a few limitations:
- Self-report measure: Results are based on subjective perception, which may vary by individual.
- Cultural Bias: While translated, some items may be interpreted differently across various cultural contexts.
- Social Desirability Bias: Patients might over-report or under-report symptoms to please their care team.
Other Versions And Related Questionnaires
While the QLQ-F17 is a standalone shortened tool, it is directly related to the EORTC QLQ-C30, which is the gold standard for cancer quality of life assessment. Additionally, researchers often use it alongside other complementary measures such as:
- FACT-G (Functional Assessment of Cancer Therapy – General)
- SF-12 (Short Form Health Survey)
Additional Resources
- The Original Development: Study Link
- You can access the questionnaire as a PDF through this link: Direct PDF Access
- For inquiries, contact the primary authors of the questionnaire: Florian Zeman (mailto:f.zeman@karldeutsch) or call (+43) 664 110 10 84.
- For additional resources, consult the EORTC Quality of Life Group
Frequently Asked Questions (FAQ)
- Who can use the EORTC QLQ-F17?
Clinicians, researchers, and healthcare providers can use the questionnaire for adult patients (aged 18+) diagnosed with any form of cancer. - How long does it take to complete?
Patients typically take only 5 to 10 minutes to complete the 17 items, making it ideal for high-volume clinics. - How is the questionnaire administered?
Healthcare teams can administer the QLQ-F17 via paper, digital platforms, or in-person interviews, offering significant flexibility. - Is there any cost to using the tool?
While it is exempt from financial charges for many users, you must obtain formal permission and sign an academic user agreement for each study.
A Word from ResRef about The European organization for research and treatment of cancer quality of life core function questionnaire (EORTC QLQ-F17)
The EORTC QLQ-F17 represents a significant advancement in patient-reported outcome measurement for oncology. By condensing the core functional scales of the widely established QLQ-C30 into a focused 17-item instrument, it offers a practical and efficient tool without sacrificing scientific rigor. Its strong psychometric properties, including high reliability and proven equivalence to the parent questionnaire, ensure data integrity for clinical and research use. The availability of professionally validated translations facilitates its global application. While access is managed through a formal permission system to maintain quality control, this process supports the sustainable development of such essential tools for improving cancer care worldwide.
References
- Zeman F, Giesinger JM, Pukrop T, Petersen MA, Groenvold M, Nolte S, Kuliś D, Shrestha S, Leysen L, Cocks K, Coens C, Ioannidis G, Pompili C, Koller M. The EORTC QLQ-F17 as a shortened version of the EORTC QLQ-C30 to assess self-reported functioning in cancer patients: investigating equivalence and psychometric properties in a randomized cross-over trial. BMC Medical Research Methodology. 2025. Link
